The estimated Net Worth of Eugene Schneider is at least $2.28 Milion dollars as of 1 February 2024. Eugene Schneider owns over 2,071 units of Ionis Pharmaceuticals Inc stock worth over $2,118,504 and over the last 4 years Eugene sold IONS stock worth over $160,168.
Sign up
Eugene Schneider IONS stock SEC Form 4 insiders trading
Eugene has made over 10 trades of the Ionis Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Eugene sold 2,071 units of IONS stock worth $102,701 on 1 February 2024.
The largest trade Eugene's ever made was exercising 25,000 units of Ionis Pharmaceuticals Inc stock on 26 December 2023 worth over $1,183,500. On average, Eugene trades about 5,214 units every 70 days since 2021. As of 1 February 2024 Eugene still owns at least 49,812 units of Ionis Pharmaceuticals Inc stock.
You can see the complete history of Eugene Schneider stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Eugene Schneider's mailing address?
Eugene's mailing address filed with the SEC is 2855 GAZELLE COURT, , CARLSBAD, CA, 92010.
Insiders trading at Ionis Pharmaceuticals Inc
Over the last 9 years, insiders at Ionis Pharmaceuticals Inc have traded over $32,069,332 worth of Ionis Pharmaceuticals Inc stock. The most active insiders traders include Stanley T Crooke, B Lynne Parshall oraz Michael R Hayden. On average, Ionis Pharmaceuticals Inc executives and independent directors trade stock every 8 days with the average trade being worth of $445,289. The most recent stock trade was executed by Richard S Geary on 28 August 2024, trading 651 units of IONS stock currently worth $32,159.
What does Ionis Pharmaceuticals Inc do?
ionis pharmaceuticals, inc., located in the north san diego county city of carlsbad, was founded in 1989 to create advanced, novel medicines to treat complex and challenging diseases. we are the pioneer in the discovery and development of antisense drugs with more than 1300 patents. ionis is a challenging, motivating and rewarding environment designed to foster innovation and scientific excellence. our founding goals have changed little in over 27 years and our success is a direct result of our outstanding employees. we are interested in bringing together individuals with different skill sets into this creative environment to be part of a productive team. join us and experience our unique culture while you develop and expand your career. for more information about ionis and to apply for an open position, please visit our website: www.ionispharma.com.
What does Ionis Pharmaceuticals Inc's logo look like?
Complete history of Eugene Schneider stock trades at Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals Inc executives and stock owners
Ionis Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Stanley Crooke,
Executive Chairman of the Board of Directors -
Brett Monia,
Chief Executive Officer, Director -
Richard Geary,
Senior Vice President - Development -
Elizabeth Hougen,
Senior Vice President, Finance and Chief Financial Officer -
Patrick O'Neil,
Senior Vice President, Legal, General Counsel, Chief Compliance Officer and Corporate Secretary -
Joan Herman,
Director -
B. Lynne Parshall,
Director -
Dr. Brett P. Monia Ph.D.,
Founder, CEO & Director -
Dr. Stanley T. Crooke,
Scientific Advisor -
Joseph Klein,
Independent Director -
Joseph Wender,
Independent Director -
Spencer Berthelsen,
Independent Director -
Breaux Castleman,
Independent Director -
Frederick Muto,
Independent Director -
Michael Hayden,
Independent Director -
Joseph Loscalzo,
Independent Director -
Peter Reikes,
Independent Director -
B. Lynne Parshall Esq., J.D.,
Sr. Strategic Advisor & Director -
C. Frank Bennett,
Chief Scientific Officer -
Dr. Richard S. Geary,
Exec. VP & Chief Devel. Officer -
Elizabeth L. Hougen,
Exec. VP of Fin. & CFO -
Patrick R. O'Neil Esq.,
Chief Legal Officer, Gen. Counsel & Corp. Sec. -
Dr. Eric E. Swayze Ph.D.,
Exec. VP of Research -
D. Wade Walke,
Investor Relations -
Onaiza Cadoret-Manier,
Chief Corporate Development and Commercial Officer -
Eric Swayze,
Senior Vice President - Research -
Dr. C. Frank Bennett,
Exec. VP & Chief Scientific Officer -
Darren Gonzales,
Chief Accounting Officer & Sr. VP -
Joel Edwards,
VP of Corp. Operations -
Damien Mc Devitt,
Chief Business Officer -
Sarah Boyce,
Chief Business Officer -
Joseph Baroldi,
EVP, Chief Business Officer -
Kyle Jenne,
EVP, Chf GL Pdt Str Ofcr -
Allene M. Diaz,
Director -
Brian Birchler,
EVP, Corp and Development Ops -
Eugene Schneider,
EVP, Chf Clinical Develop Ofcr -
Michael J. Yang,
Director